(PHR) Phreesia - Ratings and Ratios
Scheduling Software, Registration Tools, Payment Processing, Network Content
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 55.8% |
| Value at Risk 5%th | 84.8% |
| Relative Tail Risk | -7.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.59 |
| Alpha | -48.30 |
| CAGR/Max DD | -0.31 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.487 |
| Beta | 1.053 |
| Beta Downside | 0.767 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.62% |
| Mean DD | 35.56% |
| Median DD | 37.28% |
Description: PHR Phreesia November 13, 2025
Phreesia, Inc. (NYSE: PHR) operates a SaaS-based platform that digitizes front-office workflows for U.S. and Canadian healthcare providers. Its product suite spans online appointment scheduling, patient self-registration, insurance verification, point-of-sale and post-visit payment collection, plus content delivery through mobile apps, self-service tablets, web dashboards and on-site kiosks. The company serves a broad client base-from single-specialty practices to large health systems and life-science firms-leveraging a unified platform to streamline intake, improve revenue cycle efficiency, and enhance patient engagement.
Key recent metrics underscore the business’s growth trajectory: FY 2023 revenue reached $215 million, up 22 % YoY, driven largely by a 35 % increase in subscription ARR from new health-system contracts; gross margin improved to 78 % as the mix shifted toward higher-margin SaaS subscriptions; and net dollar retention exceeded 115 %, reflecting strong upsell and cross-sell activity. Primary economic drivers include accelerating adoption of digital front-end solutions amid rising healthcare spending (projected CAGR 5.5 % through 2028) and payer pressure to reduce administrative costs, while sector-wide trends such as telehealth expansion and value-based care reimbursement models further boost demand for automated intake and revenue-cycle tools.
For a deeper quantitative assessment, you may want to explore the ValueRay platform’s detailed financial models for PHR.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (-5.38m TTM) > 0 and > 6% of Revenue (6% = 27.8m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 12.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.68% (prev 19.84%; Δ 10.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 61.4m > Net Income -5.38m (YES >=105%, WARN >=100%) |
| Net Debt (-102.9m) to EBITDA (26.4m) ratio: -3.89 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.5m) change vs 12m ago 6.22% (target <= -2.0% for YES) |
| Gross Margin 68.20% (prev 67.14%; Δ 1.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 115.9% (prev 107.8%; Δ 8.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.01 (EBITDA TTM 26.4m / Interest Expense TTM 2.24m) >= 6 (WARN >= 3) |
Altman Z'' -12.15
| (A) 0.34 = (Total Current Assets 240.9m - Total Current Liabilities 98.8m) / Total Assets 423.5m |
| (B) -1.89 = Retained Earnings (Balance) -800.5m / Total Assets 423.5m |
| warn (B) unusual magnitude: -1.89 — check mapping/units |
| (C) -0.01 = EBIT TTM -2.26m / Avg Total Assets 399.6m |
| (D) -7.76 = Book Value of Equity -800.2m / Total Liabilities 103.1m |
| Total Rating: -12.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 59.86
| 1. Piotroski 6.0pt |
| 2. FCF Yield 4.68% |
| 3. FCF Margin 9.05% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -3.89 |
| 6. ROIC - WACC (= -10.55)% |
| 7. RoE -1.85% |
| 8. Rev. Trend 98.14% |
| 9. EPS Trend 94.00% |
What is the price of PHR shares?
Over the past week, the price has changed by -0.90%, over one month by -17.46%, over three months by -33.10% and over the past year by -34.79%.
Is PHR a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.8 | 80.2% |
| Analysts Target Price | 29.8 | 80.2% |
| ValueRay Target Price | 14.2 | -14.3% |
PHR Fundamental Data Overview December 22, 2025
P/E Forward = 41.3223
P/S = 2.154
P/B = 3.1148
Beta = 0.643
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 894.9m USD (997.7m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
FCF Yield = 4.68% (FCF TTM 41.9m / Enterprise Value 894.9m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 2.11 (Enterprise Value 894.9m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.27% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 9.92% (E(997.7m)/V(1.00b) * Re(9.89%) + D(3.48m)/V(1.00b) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF Debug] Terminal Value 62.60% ; FCFE base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
Fair Price DCF = 3.11 (DCF Value 187.6m / Shares Outstanding 60.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 94.00 | EPS CAGR: 135.3% | SUE: 1.52 | # QB: 1
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.37 | Chg30d=+0.080 | Revisions Net=+3 | Analysts=6
EPS next Year (2027-01-31): EPS=1.56 | Chg30d=+0.225 | Revisions Net=+6 | Growth EPS=+34.1% | Growth Revenue=+15.0%
Additional Sources for PHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle